vs
三菱重工（AIRI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是三菱重工的1.5倍（$19.6M vs $12.8M），三菱重工净利率更高（1.2% vs -177.4%，领先178.6%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -14.1%），三菱重工自由现金流更多（$-902.0K vs $-23.1M），过去两年三菱重工的营收复合增速更高（-4.5% vs -12.2%）
三菱重工業是总部位于日本东京的跨国综合工程企业，业务涵盖工程建设、电气设备与电子制造等领域，是三菱集团的核心企业之一，其原汽车事业部也是三菱汽车的前身。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AIRI vs LAB — 直观对比
营收规模更大
LAB
是对方的1.5倍
$12.8M
营收增速更快
LAB
高出2.6%
-14.1%
净利率更高
AIRI
高出178.6%
-177.4%
自由现金流更多
AIRI
多$22.2M
$-23.1M
两年增速更快
AIRI
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.8M | $19.6M |
| 净利润 | $149.0K | $-34.7M |
| 毛利率 | 14.3% | 48.5% |
| 营业利润率 | 0.7% | -168.5% |
| 净利率 | 1.2% | -177.4% |
| 营收同比 | -14.1% | -11.5% |
| 净利润同比 | 126.9% | -28.8% |
| 每股收益（稀释后） | $0.08 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIRILAB
| Q4 25 | $12.8M | — | ||
| Q3 25 | $10.3M | $19.6M | ||
| Q2 25 | $12.7M | $21.8M | ||
| Q1 25 | $12.1M | $40.8M | ||
| Q4 24 | $14.9M | — | ||
| Q3 24 | $12.6M | $22.1M | ||
| Q2 24 | $13.6M | $22.5M | ||
| Q1 24 | $14.1M | $45.5M |
净利润AIRILAB
| Q4 25 | $149.0K | — | ||
| Q3 25 | $-44.0K | $-34.7M | ||
| Q2 25 | $-422.0K | $-33.5M | ||
| Q1 25 | $-988.0K | $-26.0M | ||
| Q4 24 | $-554.0K | — | ||
| Q3 24 | $-404.0K | $-26.9M | ||
| Q2 24 | $298.0K | $-45.7M | ||
| Q1 24 | $-706.0K | $-32.2M |
毛利率AIRILAB
| Q4 25 | 14.3% | — | ||
| Q3 25 | 22.3% | 48.5% | ||
| Q2 25 | 16.0% | 48.8% | ||
| Q1 25 | 16.8% | 48.4% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 15.5% | 54.9% | ||
| Q2 24 | 19.5% | 46.1% | ||
| Q1 24 | 13.6% | 53.1% |
营业利润率AIRILAB
| Q4 25 | 0.7% | — | ||
| Q3 25 | 3.1% | -168.5% | ||
| Q2 25 | 0.1% | -118.1% | ||
| Q1 25 | -6.1% | -80.8% | ||
| Q4 24 | -0.7% | — | ||
| Q3 24 | 0.5% | -120.9% | ||
| Q2 24 | 5.5% | -134.5% | ||
| Q1 24 | -1.8% | -132.2% |
净利率AIRILAB
| Q4 25 | 1.2% | — | ||
| Q3 25 | -0.4% | -177.4% | ||
| Q2 25 | -3.3% | -153.7% | ||
| Q1 25 | -8.1% | -63.8% | ||
| Q4 24 | -3.7% | — | ||
| Q3 24 | -3.2% | -122.0% | ||
| Q2 24 | 2.2% | -203.3% | ||
| Q1 24 | -5.0% | -70.6% |
每股收益（稀释后）AIRILAB
| Q4 25 | $0.08 | — | ||
| Q3 25 | $-0.01 | $-0.09 | ||
| Q2 25 | $-0.11 | $-0.09 | ||
| Q1 25 | $-0.27 | $-0.07 | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $-0.12 | $-0.07 | ||
| Q2 24 | $0.08 | $-0.12 | ||
| Q1 24 | $-0.21 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $5.9M | — |
| 股东权益账面价值 | $19.2M | $399.7M |
| 总资产 | $58.3M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资AIRILAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $186.0K | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | $225.0K | $287.1M |
总债务AIRILAB
| Q4 25 | $5.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.4M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $5.4M | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | $4.9M | $55.0M |
股东权益AIRILAB
| Q4 25 | $19.2M | — | ||
| Q3 25 | $18.8M | $399.7M | ||
| Q2 25 | $15.3M | $424.5M | ||
| Q1 25 | $15.3M | $454.6M | ||
| Q4 24 | $14.9M | — | ||
| Q3 24 | $14.7M | $489.3M | ||
| Q2 24 | $14.9M | $510.3M | ||
| Q1 24 | $14.5M | $577.3M |
总资产AIRILAB
| Q4 25 | $58.3M | — | ||
| Q3 25 | $58.0M | $539.6M | ||
| Q2 25 | $50.4M | $557.0M | ||
| Q1 25 | $48.4M | $579.6M | ||
| Q4 24 | $51.0M | — | ||
| Q3 24 | $50.4M | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | $50.3M | $777.7M |
负债/权益比AIRILAB
| Q4 25 | 0.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.37× | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | 0.33× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-598.0K | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-902.0K | $-23.1M |
| 自由现金流率自由现金流/营收 | -7.0% | -118.1% |
| 资本支出强度资本支出/营收 | 2.4% | 4.5% |
| 现金转化率经营现金流/净利润 | -4.01× | — |
| 过去12个月自由现金流最近4个季度 | $-4.7M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流AIRILAB
| Q4 25 | $-598.0K | — | ||
| Q3 25 | $-2.6M | $-22.2M | ||
| Q2 25 | $345.0K | $-20.7M | ||
| Q1 25 | $1.5M | $-30.3M | ||
| Q4 24 | $-184.0K | — | ||
| Q3 24 | $174.0K | $-27.9M | ||
| Q2 24 | $566.0K | $-39.0M | ||
| Q1 24 | $-232.0K | $-62.5M |
自由现金流AIRILAB
| Q4 25 | $-902.0K | — | ||
| Q3 25 | $-3.5M | $-23.1M | ||
| Q2 25 | $-551.0K | $-22.6M | ||
| Q1 25 | $308.0K | $-35.3M | ||
| Q4 24 | $-985.0K | — | ||
| Q3 24 | $-95.0K | $-30.1M | ||
| Q2 24 | $-554.0K | $-41.0M | ||
| Q1 24 | $-343.0K | $-63.3M |
自由现金流率AIRILAB
| Q4 25 | -7.0% | — | ||
| Q3 25 | -34.2% | -118.1% | ||
| Q2 25 | -4.4% | -103.6% | ||
| Q1 25 | 2.5% | -86.6% | ||
| Q4 24 | -6.6% | — | ||
| Q3 24 | -0.8% | -136.4% | ||
| Q2 24 | -4.1% | -182.2% | ||
| Q1 24 | -2.4% | -138.9% |
资本支出强度AIRILAB
| Q4 25 | 2.4% | — | ||
| Q3 25 | 8.8% | 4.5% | ||
| Q2 25 | 7.1% | 8.7% | ||
| Q1 25 | 10.0% | 12.4% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 2.1% | 10.2% | ||
| Q2 24 | 8.3% | 8.6% | ||
| Q1 24 | 0.8% | 1.7% |
现金转化率AIRILAB
| Q4 25 | -4.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.90× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIRI
| Military | $7.4M | 58% |
| Other | $5.4M | 42% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
